The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study

被引：0
|
作者：
Francesco Russo
Michele Linsalata
Caterina Clemente
Benedetta D’Attoma
Antonella Orlando
Giovanna Campanella
Francesco Giotta
Giuseppe Riezzo
机构：
[1] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Biochemistry
[2] Medical Oncology Unit I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Pathophysiology
[3] Castellana Grotte,undefined
[4] Medical Oncology Unit I.R.C.C.S. “Giovanni Paolo II”,undefined
[5] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,undefined
[6] Castellana Grotte,undefined
来源：
BMC Cancer | / 13卷
关键词：
Breast cancer; Chemotherapy-induced diarrhea; Epidermal growth factor; Intestinal permeability; Ghrelin; Glucagon-like peptide 2; Gut peptides; Zonulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study
    Sakurada, Takumi
    Bando, Sanako
    Zamami, Yoshito
    Takechi, Kenshi
    Chuma, Masayuki
    Goda, Mitsuhiro
    Kirino, Yasushi
    Nakamura, Toshimi
    Teraoka, Kazuhiko
    Morimoto, Masami
    Tangoku, Akira
    Ishizawa, Keisuke
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (05) : 1107 - 1114
  • [32] Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study
    Takumi Sakurada
    Sanako Bando
    Yoshito Zamami
    Kenshi Takechi
    Masayuki Chuma
    Mitsuhiro Goda
    Yasushi Kirino
    Toshimi Nakamura
    Kazuhiko Teraoka
    Masami Morimoto
    Akira Tangoku
    Keisuke Ishizawa
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 1107 - 1114
  • [33] Good Response to Paclitaxel Predicts High Rates of Pathologic Complete Response for Breast Cancer Patients Treated Preoperatively with Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide
    Kim, Seung Jin
    Taguchi, Tetsuya
    Shimazu, Kenzo
    Tanji, Yoshio
    Tamaki, Yasuhiro
    Noguchi, Shinzaburo
    ONCOLOGY, 2009, 77 (02) : 134 - 139
  • [34] Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II-III invasive breast cancer: the OOTR-N001 study
    Chow, Louis W. C.
    Tung, Stewart Y.
    Ng, Ting-Ying
    Im, Seock-Ah
    Lee, Min-Hyuk
    Yip, Adrian Y. S.
    Toi, Masakazu
    Glueck, Stefan
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (03) : 299 - 307
  • [35] A PILOT-STUDY OF ACCELERATED CYCLOPHOSPHAMIDE, EPIRUBICIN AND 5-FLUOROURACIL PLUS GRANULOCYTE-COLONY-STIMULATING FACTOR AS ADJUVANT THERAPY IN EARLY BREAST-CANCER
    DELMASTRO, L
    GARRONE, O
    SERTOLI, MR
    CANAVESE, G
    CATTURICH, A
    GUENZI, M
    ROSSO, R
    VENTURINI, M
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (05) : 606 - 610
  • [36] Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)
    Vulsteke, C.
    Lambrechts, D.
    Dieudonne, A.
    Hatse, S.
    Brouwers, B.
    van Brussel, T.
    Neven, P.
    Belmans, A.
    Schoffski, P.
    Paridaens, R.
    Wildiers, H.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1513 - 1525
  • [37] FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)
    Aristides Polyzos
    Nikolaos Malamos
    Ioannis Boukovinas
    Adamos Adamou
    Nikolaos Ziras
    Kostas Kalbakis
    Stylianos Kakolyris
    Kostas Syrigos
    Pavlos Papakotoulas
    Charalambos Kouroussis
    Nikolaos Karvounis
    Lambros Vamvakas
    Charalambos Christophyllakis
    Athanasios Athanasiadis
    Ioannis Varthalitis
    Vassilis Georgoulias
    Dimitris Mavroudis
    Breast Cancer Research and Treatment, 2010, 119 : 95 - 104
  • [38] Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes:: vinorelbine plus epirubicin;: vinorelbine plus epirubicin sequential followed up by paclitaxel;: epirubicin plus cyclophosphamide;: epirubicin plus cyclophosphamide sequential followed up by paclitaxel.: A phase II study
    Elling, D
    Eggemann, H
    Kümmel, S
    Breitbach, P
    Kohls, A
    Morack, G
    Schlosser, H
    Krocker, J
    BREAST, 2003, 12 (03) : 208 - 211
  • [39] Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: A dose-finding study for ambulatory patients with breast cancer
    Hietanen, P
    Teerenhovi, L
    Joensuu, H
    ONCOLOGY, 1999, 56 (02) : 103 - 109
  • [40] FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)
    Polyzos, Aristides
    Malamos, Nikolaos
    Boukovinas, Ioannis
    Adamou, Adamos
    Ziras, Nikolaos
    Kalbakis, Kostas
    Kakolyris, Stylianos
    Syrigos, Kostas
    Papakotoulas, Pavlos
    Kouroussis, Charalambos
    Karvounis, Nikolaos
    Vamvakas, Lambros
    Christophyllakis, Charalambos
    Athanasiadis, Athanasios
    Varthalitis, Ioannis
    Georgoulias, Vassilis
    Mavroudis, Dimitris
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 95 - 104
12345